5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole | 952565-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-{5-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]-1,2,4-oxadiazol-3-yl}-1H-benzimidazole
• 英文别名: 5-(5-(3-(Trifluoromethyl)-4-(((2S)-1,1,1-trifluoropropan-2-yl)oxy)phenyl)-1,2,4-oxadiazol-3-yl)-1H-benzimidazole；3-(3H-benzimidazol-5-yl)-5-[3-(trifluoromethyl)-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]-1,2,4-oxadiazole
• CAS: 952565-91-2
• 化学式: C₁₉H₁₂F₆N₄O₂
• 分子量: 442.32
• InChiKey: NJNXCJPSMWKXHO-VIFPVBQESA-N

物化性质

• 沸点：
  581.1±60.0 °C(Predicted)
• 密度：
  1.463±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  76.8
• 氢给体数：
  1
• 氢受体数：
  11

制备方法与用途

ASP-4058 是一种选择性、口服活性的鞘氨醇-1-磷酸受体1和5（S1P1和S1P5）的二代激动剂，能够改善小鼠实验性自身免疫性脑脊髓炎，并且具有良好的安全性。

文献信息

• HETERO COMPOUND
  申请人：HARADA Hironori

  公开号：US20090076070A1

  公开（公告）日：2009-03-19

  [Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P 1 agonist activity. [Means for Solving] Since the compound of the invention has an S1P 1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

  [问题] 提供一种有优异S1P1激动剂活性的化合物，作为器官、骨髓或组织移植、自身免疫性疾病等引起的排异的预防和/或治疗剂的有效活性成分。 [解决方法] 由于本发明的化合物具有S1P1激动剂活性，因此可用作治疗或预防由不良淋巴细胞浸润引起的疾病的活性成分，例如器官、骨髓或组织移植的移植排斥、移植物抗宿主病、风湿性关节炎、多发性硬化症、全身性红斑狼疮、肾病综合症、脑脊髓炎、重症肌无力、胰腺炎、肝炎、肾炎、糖尿病、肺部疾病、哮喘、特应性皮炎、炎症性肠病、动脉粥样硬化、缺血再灌注损伤或异常细胞生长或积累引起的癌症和白血病等疾病。
• MEDICINAL COMPOSITION FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR SHRINKING SAME
  申请人：Kyoto University

  公开号：EP2990055A1

  公开（公告）日：2016-03-02

  Provided is a pharmaceutical composition which enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm. The pharmaceutical composition for the inhibition of formation and/or enlargement of cerebral aneurysm or for the regression of cerebral aneurysm of the present invention, which includes a S1P1 receptor agonist as an active ingredient, enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm, and enables the prevention and/or treatment of a disease associated with cerebral aneurysm.

  本发明提供了一种能够抑制脑动脉瘤形成和/或扩大或使脑动脉瘤消退的药物组合物。本发明的抑制脑动脉瘤形成和/或增大或使脑动脉瘤消退的药物组合物，其活性成分包括 S1P1 受体激动剂，可抑制脑动脉瘤形成和/或增大或使脑动脉瘤消退，并可预防和/或治疗与脑动脉瘤相关的疾病。
• MEDICINE FOR PREVENTING OR TREATING OPHTHALMIC DISEASE ASSOCIATED WITH ENHANCED INTRAOCULAR NEOVASCULARIZATION AND/OR INTRAOCULAR VASCULAR PERMEABILITY
  申请人：Kyoto University

  公开号：EP3747471A1

  公开（公告）日：2020-12-09

  Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention. A compound or a pharmaceutically acceptable salt thereof of the present invention, which serves as the selective S1P receptor agonist having agonist activity at the S1P1 receptor, has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, and can be used as a preventive and/or therapeutic agent for, for example, exudative age-related macular degeneration, diabetic retinopathy, diabetic macular edema, myopic choroidal neovascularization, retinal artery occlusion, retinal vein occlusion, or neovascular glaucoma.

  本发明提供了一种用于预防或治疗与眼内新生血管和/或眼内血管通透性增加有关的眼科疾病的药物。本发明的发明者对一种用于预防或治疗与眼内新生血管化和/或眼内血管通透性增加相关的眼科疾病的药物进行了研究，并证实了一种对 S1P1 受体具有激动活性的选择性 S1P 受体激动剂具有降低眼内新生血管化作用和降低眼内血管通透性作用，从而完成了本发明。本发明的化合物或其药学上可接受的盐作为选择性 S1P 受体激动剂，在 S1P1 受体上具有激动活性，具有降低眼内新生血管作用和降低眼内血管通透性作用、本发明可用作渗出性老年性黄斑变性、糖尿病视网膜病变、糖尿病黄斑水肿、近视性脉络膜新生血管、视网膜动脉闭塞、视网膜静脉闭塞或新生血管性青光眼等疾病的预防和/或治疗药物。
• Oxadiazole derivatives as S1P1 agonists
  申请人：Astellas Pharma Inc.

  公开号：EP2003132B1

  公开（公告）日：2014-03-05
• COMPOSITION COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST FOR INHIBITING FORMATION AND/OR ENLARGEMENT OF CEREBRAL ANEURYSM OR FOR SHRINKING IT
  申请人：Kyoto University

  公开号：EP2990055B1

  公开（公告）日：2019-06-05